Pre-existing and acquired resistance to PARP inhibitor-induced synthetic lethality
BV Le, P Podszywałow-Bartnicka, K Piwocka, T Skorski - Cancers, 2022 - mdpi.com
Simple Summary PARP inhibitors (PARPi) have been administered to treat BRCA1/2-
mutated/deficient malignancies. Nevertheless, the resistance to PARPi is emerging in …
mutated/deficient malignancies. Nevertheless, the resistance to PARPi is emerging in …